Table 3. Base-Case Costs Estimates and Utilities.
| Parameter | Expected Values (Ranges) | Distribution (Parameters) | Description and Reference |
|---|---|---|---|
| Costs (US $) | |||
| Cost of pemetrexed per 500 mg | 967.57 (533.02-2126.51) | Gamma (2303, 0.42) | [43] |
| Cost of the chemotherapy excluding the non-platinum agents per 21-day cycle | 518.4 (388.8-648) | Gamma (4064.3, 0.13) | [43] |
| Cost of icotinib per day | 31.72 (15.86-31.72) | Gamma (248.7, 0.13) | Local charge |
| Cost of gefitinib per day | 37.43 (18.71-37.43) | Gamma (293.4, 0.13) | Local charge |
| Cost of follow-up per unit | 55.6 (41.7-69.4) | Gamma (437.5, 0.13) | [43] |
| Cost of salvage chemotherapy per cycle | 2352.7 (1921.1-4383.3) | Gamma (8812.4, 0.27) | [43] |
| Cost of palliative care in end-of-life | 2042.91 (793.65-5456.19) | Gamma (3508.8, 0.58) | [43] |
| Cost of supportive care per cycle | 337.5 (158.7-793.7) | Gamma (703.2, 0.48) | [43] |
| Cost of SAEs per unit | 507.4 (189.7-825.0)) | Gamma (1588.6, 0.32) | [43] |
| Cost of EGFR mutation testing | 380.95 (158.73-476.19) | Gamma (1792, 0.21) | Local charge |
| Utilities | |||
| Utility of PFS | 0.82 (0.78-0.86) | Beta (373.6, 82) | [44, 45] |
| Utility of OS | 0.58 (0.5-0.66) | Beta (84, 60.9) | [44, 45] |
| Disutility of SAEs | 0.35 (0.31-0.39) | Beta (199.1, 369.7) | [44] |
EGFR: epidermal growth factor receptor; SAEs: serious adverse events (≥grade 3); PFS: progression-free survival; OS: overall survival.